CAPR vs. CNTA, MIRM, GMTX, BLTE, ARWR, LGND, HRMY, ARQT, JANX, and TVTX
Should you be buying Capricor Therapeutics stock or one of its competitors? The main competitors of Capricor Therapeutics include Centessa Pharmaceuticals (CNTA), Mirum Pharmaceuticals (MIRM), Gemini Therapeutics (GMTX), Belite Bio (BLTE), Arrowhead Pharmaceuticals (ARWR), Ligand Pharmaceuticals (LGND), Harmony Biosciences (HRMY), Arcutis Biotherapeutics (ARQT), Janux Therapeutics (JANX), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical preparations" industry.
Capricor Therapeutics vs.
Centessa Pharmaceuticals (NASDAQ:CNTA) and Capricor Therapeutics (NASDAQ:CAPR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk, institutional ownership and community ranking.
In the previous week, Capricor Therapeutics had 25 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 39 mentions for Capricor Therapeutics and 14 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.68 beat Capricor Therapeutics' score of 0.35 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media.
Centessa Pharmaceuticals has a net margin of 0.00% compared to Capricor Therapeutics' net margin of -146.86%. Centessa Pharmaceuticals' return on equity of -52.13% beat Capricor Therapeutics' return on equity.
Capricor Therapeutics received 329 more outperform votes than Centessa Pharmaceuticals when rated by MarketBeat users. Likewise, 63.78% of users gave Capricor Therapeutics an outperform vote while only 59.26% of users gave Centessa Pharmaceuticals an outperform vote.
Centessa Pharmaceuticals has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500. Comparatively, Capricor Therapeutics has a beta of 4.1, meaning that its stock price is 310% more volatile than the S&P 500.
82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are owned by institutional investors. 11.6% of Centessa Pharmaceuticals shares are owned by company insiders. Comparatively, 12.0% of Capricor Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Capricor Therapeutics has higher revenue and earnings than Centessa Pharmaceuticals. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Centessa Pharmaceuticals presently has a consensus target price of $26.00, indicating a potential upside of 60.30%. Capricor Therapeutics has a consensus target price of $34.50, indicating a potential upside of 162.96%. Given Capricor Therapeutics' higher possible upside, analysts plainly believe Capricor Therapeutics is more favorable than Centessa Pharmaceuticals.
Summary
Capricor Therapeutics beats Centessa Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Capricor Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Capricor Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CAPR) was last updated on 3/25/2025 by MarketBeat.com Staff
